the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title CANTATA: CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Official Title A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) - CANTATA
Principal Investigator Stadler, Walter
Brief Summary This study is a randomized Phase 2 evaluation of CB-839 in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic Renal Cell Carcinoma.
Gender All
Ages 18 Years
Enrollment 298
Accepts Healthy Volunteers No
Lead Sponsor Calithera Biosciences, IncIndustry
Collaborator
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name Maurice Markus, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Advanced Renal Cell Carcinoma
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI